GC
TVTX icon

Guggenheim Capital’s Travere Therapeutics TVTX Stock Holding History

Guggenheim Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Buy
46,118
+8,915
+24% +$267K 0.01% 856
2025
Q4 		$1.42M Buy
37,203
+27,901
+300% +$907K 0.01% 781
2025
Q3 		$222K Buy
+9,302
New +$175K ﹤0.01% 1491

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Guggenheim Capital's TVTX Position: Q1 2026 in Review

Guggenheim Capital increased its Travere Therapeutics (TVTX) stake by 24% in Q1 2026, buying an estimated $267K and bringing the position to 46,118 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #856.

Guggenheim Capital first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.42M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Guggenheim Capital held 46,118 shares of Travere Therapeutics worth $1.37M as of Q1 2026.
  • Guggenheim Capital bought 8,915 Travere Therapeutics shares in Q1 2026, an estimated $267K.
  • Travere Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #856 holding.
  • Guggenheim Capital first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Guggenheim Capital's Travere Therapeutics position peaked at $1.42M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.